| Name | Title | Contact Details |
|---|
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.
Get tested for a healthier lifestyle. We offer at-home genetic test for fitness, health and even food sensitivities. Test your DNA today!
In 1998, RPS began building the foundation for the PRO model in anticipation of evolving clinical strategies within Sponsor companies. By integrating its personnel and systems with those of Sponsor companies, RPS has helped industry leaders achieve significant cost savings, flexible program staffing, and standardized system operations on a global scale.
Cofounded by Frank M. Reynolds, MIT`s Dr. Robert S. Langer, Katrin Holzhaus, and Dr. Jason Criscione, PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson`s disease, and spinal cord injury.